Only 17% of pharmacy executives are optimistic

As the British government cabinet and the European Union agree to the Brexit plan of British Prime Minister Wen Cuishan, the final level will be considered in the British Parliament next Tuesday (11th). If the plan is rejected, the UK and the EU must renegotiate, the worst case. It is the so-called “hard Brexit” no-deal Brexit. According to a recent survey released by research firm GlobalData last week, only 17% of UK pharmaceutical executives believe that the UK will maintain its scientific and commercial appeal after Brexit. The local business community also needs to solve many unknowns such as data, talent flow, customs clearance, and even worry about the R&D funds being cut.

Chamber of Commerce is afraid that data exchange will not be smooth

Representatives of several UK biotech start-up companies have pointed out that the biggest worry about Brexit is whether talents and data can flow freely between EU countries and the UK. Steve Bates, chief executive of the BioIndustry Association (BIA), said that because of the relocation of the European Medicines Agency (EMA), many research projects have been postponed. “Unfortunately, we should spend more time developing New treatments, not moving office buildings.”

It is common for multinational and cross-laboratory research and development. Bates means that time zones, transportation and logistics will affect cooperation. It also pays attention to the data generated in the UK when it is handed over to drug regulatory agencies in the United States, China, and the European Union. Whether it becomes complicated. Although he is optimistic that the basic principles will not change, the formal commerce and customs clearance procedures are still unknown. Clustermarket CEO Johannes Solzbach does not rule out that research institutions will be cut back after Brexit.

According to Catherine McGuinness, Chairman of the City of London Policy and Resources Committee, the industry is most worried about whether the UK can maintain a rational immigration policy in case of a hard break, so that the company can successfully hire and retain the required talents within a reasonable time. .

McGuinness also mentioned that London has always focused not only on the European market, but also that the UK will continue to be attractive after the Brexit. “Of course, Brexit will have a short-term impact on the business environment, but London has always had so many opportunities. Overshadowed.”